DDX53 and triple-negative breast carcinoma: However, these murine tumors differ in their TME immune contexture, as CT26 responds to immune checkpoint inhibitors while 4T1 is considered cold and mimics triple-negative breast cancer which is highly resistant to immune checkpoint therapies [45,46].